Exploring novel perspectives on eosinophilic inflammation in severe asthma

Biomark Med. 2024 Apr 16. doi: 10.2217/bmm-2023-0801. Online ahead of print.ABSTRACTTwo recent articles by the same research group documented that patients with severe eosinophilic asthma exhibit an increased proportion of a subtype of eosinophils, namely CD62Llow inflammatory eosinophils (iEos) and identified an intriguing correlation between such iEos and asthma control scores. Moreover, CD62Llow iEos were reduced after treatment with the anti-IL-5 monoclonal antibody mepolizumab. In the future, we believe that eosinophil subtypes could represent a useful biomarker in severe eosinophilic asthma, helping clinicians characterize patient endotypes and monitoring the response to biological drugs.PMID:38623926 | DOI:10.2217/bmm-2023-0801
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Authors: Source Type: research